Myotonic Dystrophy Type 2 Overview

Save information for later
Sign Up

Learn About Myotonic Dystrophy Type 2

What is the definition of Myotonic Dystrophy Type 2?
Myotonic dystrophy type 2, one of the two types of myotonic dystrophy, is an inherited muscular dystrophy that affects the muscles and other body systems (e.g., heart, eyes, and pancreas). It is characterized by prolonged muscle tensing (myotonia) as well as muscle weakness, pain, and stiffness. Signs and symptoms usually develop during a person's twenties or thirties. Muscles in the neck, fingers, elbows, and hips are typically affected; facial and ankle muscles are less commonly involved. The severity of Myotonic dystrophy type 2 varies widely among affected people, even among family members. It is inherited in an autosomal dominant pattern and is caused by genetic changes in the CNBP gene.
What are the alternative names for Myotonic Dystrophy Type 2?
  • Myotonic dystrophy type 2
  • DM2
  • Dystrophia myotonica type 2
  • Myotonic myopathy, proximal
  • PROMM
  • Proximal myotonic myopathy
  • Ricker syndrome
Who are the top Myotonic Dystrophy Type 2 Local Doctors?
Elite in Myotonic Dystrophy Type 2
Giovanni Meola
Elite in Myotonic Dystrophy Type 2
Giovanni Meola
Milan, IT 

Giovanni Meola practices in Milan, Italy. Mr. Meola is rated as an Elite expert by MediFind in the treatment of Myotonic Dystrophy Type 2. His top areas of expertise are Myotonic Dystrophy Type 2, Paramyotonia Congenita, Myotonic Dystrophy, Amyotonia Congenita, and Thymectomy.

Elite in Myotonic Dystrophy Type 2
Stojan Z. Peric
Elite in Myotonic Dystrophy Type 2
Stojan Z. Peric
6, Dr. Subotic Sr. Street, 11 000, 
Belgrade, SE, RS 

Stojan Peric practices in Belgrade, Serbia. Peric is rated as an Elite expert by MediFind in the treatment of Myotonic Dystrophy Type 2. Their top areas of expertise are Myotonic Dystrophy Type 2, Myotonic Dystrophy, Paramyotonia Congenita, and Myasthenia Gravis.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Myotonic Dystrophy Type 2
Dr. Chad R. Heatwole
Neurology
Elite in Myotonic Dystrophy Type 2
Dr. Chad R. Heatwole
Neurology

University Of Rochester

601 Elmwood Ave, 
Rochester, NY 
585-275-2100
Languages Spoken:
English
See accepted insurances

Chad Heatwole is a Neurologist in Rochester, New York. Dr. Heatwole is rated as an Elite provider by MediFind in the treatment of Myotonic Dystrophy Type 2. His top areas of expertise are Myotonic Dystrophy Type 2, Myotonic Dystrophy, Paramyotonia Congenita, and Facioscapulohumeral Muscular Dystrophy (FSHD).

View All Doctors
What are the latest Myotonic Dystrophy Type 2 Clinical Trials?
A Randomized, Placebo-Controlled, Multiple Ascending Dose Study Assessing Safety, Tolerability, Pharmacodynamics, Efficacy, and Pharmacokinetics of DYNE-101 Administered to Participants With Myotonic Dystrophy Type 1
A Randomized, Placebo-Controlled, Multiple Ascending Dose Study Assessing Safety, Tolerability, Pharmacodynamics, Efficacy, and Pharmacokinetics of DYNE-101 Administered to Participants With Myotonic Dystrophy Type 1
Enrollment Status: Recruiting
Publish Date: December 17, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2

Summary: The primary purpose of the study is to evaluate the safety and tolerability of multiple intravenous (IV) doses of DYNE-101 administered to participants with Myotonic Dystrophy Type 1 (DM1). The study consists of 4 periods: A Screening Period (up to 8 weeks), a Placebo-Controlled Period (24 weeks), a Treatment Period (24 weeks) and a Long-Term Extension (LTE) Period (168 weeks) in both multiple-asc...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 1/2, Randomized, Double-blind, Placebo-controlled Single- and Multiple-dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VX-670 in Adult Subjects With Myotonic Dystrophy Type 1
A Phase 1/2, Randomized, Double-blind, Placebo-controlled Single- and Multiple-dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VX-670 in Adult Subjects With Myotonic Dystrophy Type 1
Enrollment Status: Recruiting
Publish Date: December 15, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2

Summary: The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of VX-670 at different single and multiple doses in participants with DM1.

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center